Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Quest Diagnostics lifts FY outlook after broad-based growth powers Q2 beat

Quest Diagnostics lifts FY outlook after broad-based growth powers Q2 beat

ReutersReuters2026/07/23 11:00
By:Reuters


Overview

  • US diagnostic testing firm's Q2 revenue rose 10%, beating analyst expectations

  • Adjusted EPS for Q2 increased 19%, beating analyst expectations

  • Company raised full-year 2026 revenue and adjusted EPS guidance


Outlook

  • Quest Diagnostics raises 2026 revenue outlook to $11.95 bln-$12.05 bln from $11.78 bln-$11.90 bln

  • Company lifts 2026 reported diluted EPS forecast to $9.97-$10.17 from $9.58-$9.78

  • Quest Diagnostics expects 2026 adjusted diluted EPS of $11.05-$11.25, up from $10.63-$10.83


Result Drivers

  • ORGANIC GROWTH - Nearly all revenue growth came from organic gains across physician, hospital, and consumer channels

  • ADVANCED DIAGNOSTICS - Double-digit revenue growth in Advanced Diagnostics, including Alzheimer's and cardiometabolic tests, contributed to results

  • CONSUMER CHANNELS - Robust revenue growth from questhealth.com and consumer, wearable, and wellness partners supported results


Company press release: ID:nPn70YzCXa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$3.04 bln

$2.97 bln (14 Analysts)

Q2 Adjusted EPS

Beat

$3.12

$2.83 (15 Analysts)

Q2 EPS

$2.84

Q2 Net Income

$320 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities services peer group is "buy"

  • Wall Street's median 12-month price target for Quest Diagnostics Inc is $225.00, about 7.2% above its July 22 closing price of $209.83

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago


Reuters Recommended Reads

  • July 23 - France's Eurofins H1 revenue up 2.5% on investment in laboratory network

  • July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook

  • July 20 - Tempus to acquire Personalis for $1.5 billion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!